Arrowhead Pharmaceuticals, Inc.
ARWR
$16.97
-$0.70-3.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.49% | 0.15% | -36.31% | 5.69% | -21.14% |
| Total Depreciation and Amortization | 4.18% | 5.08% | 5.68% | 6.15% | 10.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.64% | -21.60% | 3.67% | 15.70% | 2.43% |
| Change in Net Operating Assets | -193.56% | -67.73% | 631.71% | 130.98% | -118.50% |
| Cash from Operations | -6.60% | -18.89% | -24.94% | 21.61% | -354.52% |
| Capital Expenditure | 69.06% | -68.10% | 57.60% | 50.37% | -7.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.50% | -1,028.28% | 109.11% | -275.93% | 41.39% |
| Cash from Investing | 134.50% | -3,307.99% | 102.58% | -514.78% | 112.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 184.30% | -42.38% | -99.91% | 161,239.70% | -67.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 738.16% | -106.27% | -- | -- | -- |
| Cash from Financing | -94.70% | 672.20% | -88.30% | 161,239.70% | -67.48% |
| Foreign Exchange rate Adjustments | -101.57% | 2,044.39% | -957.69% | -55.17% | -62.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.60% | 157.09% | -183.91% | 231.92% | -1,047.92% |
